OPKO Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Phillip Frost
- Full Time Employees
- 2,275
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 4400 Biscayne Boulevard Miami FL United States of America 33137
- IPO Date
- Nov 2, 1995
- CIK
- 0000944809
- Website
- opko.com
- Similar Companies
- Business
- OPKO Health, Inc. is a diversified healthcare company engaged primarily in the development and commercialization of pharmaceuticals, diagnostics, and nutritional products. The company offers an extensive portfolio that includes branded and generic pharmaceuticals; innovative diagnostic products and services, including laboratory testing; and nutritional products targeting cardiovascular, metabolic, and other health conditions. Core products include eye care pharmaceuticals such as Rayaldee for secondary hyperparathyroidism; bio-analytical testing services through its CLIA-certified laboratories; and novel therapeutics in oncology, endocrinology, and infectious diseases. OPKO also develops and markets vitamin and supplement lines. OPKO operates globally with significant presence in the United States, Latin America, and Europe, serving a broad range of customers including healthcare providers, hospitals, and consumers. Founded in 2007 and headquartered in Miami, Florida, the company continues to expand its footprint by leveraging its proprietary technologies and strategic partnerships. In the last 1-2 years, OPKO has focused on strategic expansion through key acquisitions and partnerships, aimed at enhancing its diagnostics capabilities and diversifying its pharmaceutical pipeline. Notably, it has launched several new diagnostic tests to capitalize on growing demand for advanced laboratory services. The company has also pursued collaborations with biotechnology firms to accelerate development of innovative therapeutics. Additionally, OPKO maintains active efforts to streamline operations and optimize its product portfolio to align with evolving market needs. Overall, OPKO Health stands as an integrated healthcare enterprise with operations spanning pharmaceuticals, diagnostics, and nutrition, with recent strategic initiatives reflecting its commitment to innovation and growth in multiple therapeutic and diagnostic domains.
Company News
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Comparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)
OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated “Hold” by Sell-Side Analysts
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
Analyzing HCA Healthcare (NYSE:HCA) & OPKO Health (NASDAQ:OPK)
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Connor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPK
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPK Raises $125 Million Against Royalties: What Investors Should Know
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know